We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

EUROIMMUN AG

EUROIMMUN is an international provider of medical laboratory products for autoimmune, infection, allergy and molecula... read more Featured Products: More products

Download Mobile App




Antiphospholipid Antibodies in Patients With Unexplained Articular Manifestations

By LabMedica International staff writers
Posted on 21 Dec 2022
Print article
Image: The SFRI IRE 96 is a simple and robust ELISA Absorbance Microplate Reader finds application in ELISA assays (Photo courtesy of HealthManagement.org)
Image: The SFRI IRE 96 is a simple and robust ELISA Absorbance Microplate Reader finds application in ELISA assays (Photo courtesy of HealthManagement.org)

Joint pain is the most common chronic pain making it one of the largest causes of disabilities in the world. Arthritis is a frequent condition that causes edema, redness, heat, loss of function and pain. It can affect one or more joints and there exist more than 100 different types.

Antiphospholipid antibodies (aPL) represent a complex and heterogeneous group of antibodies directed against anionic phospholipids or protein-phospholipid complexes. Persistent aPL have been associated with antiphospholipid syndrome (APS), which is defined by the presence of recurrent venous and/or arterial thrombosis and often pregnancy morbidity.

Immunologists at the Farhat Hached Hospital (Sousse, Tunisia) and their colleagues conducted a retrospective study including 313 patients suffering from arthritis or arthralgia without evident cause. Serum samples were collected from January 2017 to December 2019. Antinuclear antibodies (ANA), rheumatoid factors (RF) and anti-cyclic citrullinated peptides antibodies (CCP-Ab) were negative for all patients. Sera of 266 healthy blood donors (HBD) were included as normal controls.

The team detected aCL-IgG and IgM using an enzyme-linked immunosorbent assay (ELISA) kit and aCL-IgA were assessed by ELISA kit (Orgentec Diagnostika, Mainz, Germany). Highly purified cardiolipin was coated on microwells with β2GPI. Specific antibodies in the patient sample bound to antigen. microtiter plate reader and results were detected with an IRE 96microtiter plate reader (SFRI Medical Diagnostics, Saint Jean d'Illac, France). The scientists evaluated aβ2GPI-IgG and IgM by an ELISA kit (Orgentec Diagnostika) using a purified human β2GPI. aβ2GPI-IgA were assessed by ELISA kit. RF IgG, IgM and IgA were assessed using a three commercially ELISA kits, (Orgentec Diagnostika). CCP-Ab were measured by an available second-generation ELISA and ANA were detected by indirect immunofluorescence on HEp-2 cells (Euroimmun, Luebeck, Germany).

The investigators reported that out of the 313 patients, 250 were females and 63 were males. The mean age of patients was 49 ± 14 years (17–87 years). One hundred eleven patients have arthralgia and 202 have arthritis. The frequency of aCL and/or aβ2GPI (24.9%) was significantly higher in patients than in HBD (10.9%). The frequency of aβ2GPI was 23.6% in patients and 9.4% in the control group. aβ2GPI-IgA was significantly more frequent in patients than in the control group (20.4% versus 7.5%. aβ2GPI was most commonly observed than aCL in patients (23.6% versus 6.4%. IgA isotype of aβ2GPI was the most frequent in 20.4% of patients while IgG and IgM were detected in 5.4% and 2.9% respectively.

The authors concluded that they had demonstrated an elevated frequency of aβ2GPI-IgA in patients with unexplained arthralgia or arthritis. The possible pathogenic mechanism of aβ2GPI remained to be demonstrated and a prospective study is necessary to known if aβ2GPI-IgA will persist over time. The study was published on December 13, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
Farhat Hached Hospital
Orgentec Diagnostika
SFRI Medical Diagnostics
Euroimmun

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.